Skip to main content
SpringerLink
Log in

Infliximab

Drop in systolic BP: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Robinson K, et al. Accelerated infusions of biosimilar infliximab are safe and well tolerated and monitoring post-infusion is not required. Journal of Crohn's and Colitis 11 (Suppl. 1): S492-S493, Feb 2017. Available from: URL: http://doi.org/10.1093/ecco-jcc/jjx002.927 [abstract] - United Kingdom

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Infliximab. Reactions Weekly 1696, 205 (2018). https://doi.org/10.1007/s40278-018-44393-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44393-2

Search

Navigation